House Bill 1102, introduced by Illinois Representative Jed Davis on March 19, 2025, aims to enhance cancer screening coverage under the Illinois Insurance Code, specifically targeting ovarian cancer. This legislative proposal seeks to redefine the criteria for individuals considered "at risk for ovarian cancer" by including those with elevated levels of the CA-125 protein, as indicated by blood tests.

The bill expands the definition of "surveillance tests for ovarian cancer" to encompass a broader range of diagnostic methods, such as ultrasounds, MRIs, CT scans, and CA-125 blood tests. This change moves away from the previous requirement of annual screenings that were limited to specific tests, thereby allowing for more comprehensive monitoring of ovarian cancer risk. If passed, these provisions would take effect on January 1, 2027.

The introduction of HB 1102 has sparked discussions among healthcare advocates and insurance providers. Proponents argue that the bill addresses a critical gap in cancer detection, particularly for women who may not have been adequately screened under the previous guidelines. They emphasize that early detection can significantly improve treatment outcomes and survival rates for ovarian cancer, which is often diagnosed at a later stage.

However, the bill has faced some opposition, particularly from insurance companies concerned about the potential increase in costs associated with broader coverage requirements. Critics argue that the expanded definition of at-risk individuals could lead to higher premiums for policyholders.

The implications of HB 1102 extend beyond just healthcare access; they touch on broader social issues, including health equity. By ensuring that more women have access to necessary screenings without financial barriers, the bill could help reduce disparities in cancer outcomes among different demographic groups.

As the legislative process unfolds, stakeholders are closely monitoring the bill's progress. If passed, House Bill 1102 could represent a significant step forward in cancer care in Illinois, potentially setting a precedent for similar initiatives in other states. The ongoing debates surrounding the bill highlight the delicate balance between expanding healthcare access and managing costs within the insurance industry.